chartexchange

Zura Bio Limited (ZURA) Securities Investigation Notice - Levi & Korsinsky

PR Newswire | Nov 16, 2026 10:01 AM EST

ZURA shareholders saw their shares decline approximately 72% at market open after the Company disclosed that its Phase 2 TibuSHIELD trial of tibulizumab failed to meet its primary endpoint at either dose tested. Investors who took that loss may be eligible to seek a recovery as an...

Read original article